This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

A randomized double-blind study comparing 25 and 50 mg TC-1734 (AZD3480) with placebo, in older subjects with age-associated memory impairment


Dunbar, Geoffrey C., Kuchibhatla, Ramana V., Lee, G.


Journal Of Psychopharmacology (Oxford, England), Volume: 25, No.: 8, Pages.: 1020-1029

Year of Publication



Cognitive decline is a feature of ageing and can be defined as normal (age-associated memory impairment) or pathological (mild cognitive impairment/Alzheimer’s disease). Stimulation of selective brain-specific neuronal nicotinic acetylcholine receptors might offer symptomatic treatment for normal ageing. The objective of this study was to assess the safety, tolerability and efficacy of TC-1734 (AZD3480), a selective α4β2 nicotinic agonist, in the treatment of age-associated memory impairment. A randomized placebo-controlled trial was conducted in 16 community-based centers within the USA. Subjects who met objective criteria for age-associated memory impairment were recruited between November 2004 and December 2005. Subjects were randomly assigned to receive orally 25 mg (n = 59), 50 mg (n = 68) TC-1734 (AZD3480) or placebo (n = 66) in a double-blind fashion for 16 weeks. Main outcome measures included routine clinical safety measures, tolerability, cognitive assessment via the Cognitive Drug Research computerized test battery and a Subject Global Impression Scale of Cognition (SCI-Cog). Two outcomes from the computerized test battery – a factor assessing attention and one assessing episodic memory, along with the SGI-Cog were defined as co-primary outcome variables. Baseline to Week 16 differences from placebo for 50 mg TC-1734 (AZD3480) were considered of primary importance. For 50 mg TC-1734 (AZD3480) attention factor the mean drug-placebo difference was 22.9 (95% confidence interval 4.8 to 41.4) p = 0.01 for episodic memory factor the difference was -7.6 (95% confidence interval -14.4 to -0.8), p = 0.029, and for the SGI-Cog the difference was 0.99 (95% confidence interval 0.2 to 1.8), p = 0.015. As all three co-primary outcomes were positive it can be concluded the compound likely had a beneficial effect on cognition. TC-1734 (AZD3480) appeared safe and well tolerated in this study.;

Bibtex Citation

@article{Dunbar_2010, doi = {10.1177/0269881110367727}, url = {}, year = 2010, month = {jun}, publisher = {{SAGE} Publications}, volume = {25}, number = {8}, pages = {1020--1029}, author = {G. C. Dunbar and R. V. Kuchibhatla and G. Lee}, title = {A randomized double-blind study comparing 25 and 50 mg {TC}-1734 ({AZD}3480) with placebo, in older subjects with age-associated memory impairment}, journal = {Journal of Psychopharmacology} }


administration & dosage, administration oral, adverse effects, aged, aged, 80 and over, agonist, cognition disorders, double-blind method, drug therapy, female, humans, male, medication, memory disorders, middle aged, nicotinic, pyridines, therapeutic use, tolerability, treatment outcome

Countries of Study


Types of Dementia

Alzheimer’s Disease, Mild Cognitive Impairment (MCI)

Types of Study

Randomised Controlled Trial

Type of Outcomes

Cognition, Other



Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions